DaVita (NYSE:DVA - Get Free Report) issued its earnings results on Monday. The company reported $2.00 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.75 by $0.25, Zacks reports. DaVita had a net margin of 7.31% and a return on equity of 115.48%. DaVita updated its FY 2025 guidance to 10.200-11.300 EPS.
DaVita Stock Up 0.4%
DaVita stock traded up $0.53 on Monday, hitting $144.29. 1,275,522 shares of the stock traded hands, compared to its average volume of 820,697. The company has a current ratio of 1.26, a quick ratio of 1.21 and a debt-to-equity ratio of 23.18. The firm has a market cap of $11.09 billion, a P/E ratio of 13.43, a price-to-earnings-growth ratio of 1.07 and a beta of 1.14. The business's fifty day simple moving average is $145.85 and its 200 day simple moving average is $153.83. DaVita has a 1 year low of $131.44 and a 1 year high of $179.60.
Analyst Ratings Changes
DVA has been the topic of several recent analyst reports. StockNews.com upgraded shares of DaVita from a "hold" rating to a "buy" rating in a report on Friday, April 25th. Barclays raised their target price on shares of DaVita from $164.00 to $169.00 and gave the stock an "equal weight" rating in a report on Tuesday, February 18th. Cowen reiterated a "hold" rating on shares of DaVita in a report on Tuesday, February 18th. Finally, Sanford C. Bernstein set a $184.00 price target on shares of DaVita in a report on Friday, February 21st. One investment analyst has rated the stock with a sell rating, four have given a hold rating and two have assigned a buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of "Hold" and an average target price of $166.33.
Check Out Our Latest Report on DaVita
About DaVita
(
Get Free Report)
DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider DaVita, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and DaVita wasn't on the list.
While DaVita currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
